Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart attack care: should doctors fix all blockages at once or wait?

NCT ID NCT04968808

Disease control Sponsor: Chonnam National University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 29, 2026 · Updated 5 times

Summary

This study looks at the best timing for opening blocked arteries in people having a certain type of heart attack (NSTEMI) who have multiple blockages. About 1,014 participants will be randomly assigned to have all blockages fixed during the same procedure or to wait a few days between procedures. The goal is to see which approach reduces the chance of death, another heart attack, or needing another procedure within a year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
staged or immediate heart procedure (angioplasty with stents)
What this could lead to
If successful, this could show that doing all heart procedures at once is safer and more effective than waiting days between procedures for NSTEMI patients.
What could go wrong
This is a single-center trial, and results may not apply to all hospitals. The benefit of immediate versus staged procedures may be small, and there is a risk of kidney damage from contrast dye.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,014 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2021

Expected to finish

Aug 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 19 years old 2. Non-ST-segment elevation myocardial infarction * Angina pectoris or equivalent ischemic chest discomfort with at least 1 of 3 features and, * occurs at rest, usually lasting \> 10 minutes * severe and new onset (within the prior 4-6 weeks) * crescendo pattern * Elevated cardiac biomarkers and, * ≥ 99% value of high-sensitivity cardiac troponin * No ST-segment elevation ≥ 0.1 mV in ≥ 2 contiguous leads or newly developed left bundle branch block on 12-lead electrocardiogram 3. PCI within 72 hours after symptom development 4. Multivessel disease: Non-IRA with at least 2.5 mm diameter and 50% diameter stenosis by visual estimation 5. Patient's or protector's agreement about study design and the risk of PCI Exclusion Criteria: 1. Cardiogenic shock at initial presentation or after treatment of IRA 2. TIMI flow at non-IRA ≤ 2 3. Severe procedural complications (e.g. persistent no-reflow phenomenon, coronary artery perforation) which restricts study enrollment by operators' decision 4. Non-IRA lesion not suitable for PCI treatment by operators' decision 5. Chronic total occlusion at non-IRA 6. History of anaphylaxis to contrast agent 7. Pregnancy and lactation 8. Life expectancy \< 1-year 9. Severe valvular disease 10. History of CABG, or planned CABG 11. Fibrinolysis before admission

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multi vessel coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myocardial infarction coronary artery disorder coronary stenosis myocardial infarction ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multi vessel coronary artery disease Multi-vessel coronary artery stenosis Myocardial infarction, acute

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chonnam National University Hospital

    RECRUITING

    Gwangju, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.